64th ASH Annual Meeting and Exposition: 602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies

Symposia: Myeloid Oncogenesis: Basic Oral and Poster Abstracts
Oral

Research, Fundamental Science, Lymphoid Leukemias, ALL, Antibody Therapy, Biological therapies, Acute Myeloid Malignancies, AML, Lymphomas, non-Hodgkin lymphoma, Translational Research, CHIP, genomics, Plasma Cell Disorders, Clinical Research, hematopoiesis, Diseases, immune mechanism, indolent lymphoma, Therapies, immunology, aggressive lymphoma, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes, Technology and Procedures, molecular biology, Minimal Residual Disease , molecular testing

353-355 (Ernest N. Morial Convention Center)

Moderators:

Andre Catic, MD, PhD, Baylor College of Medicine and Ann Mullally, MD, Brigham and Women's Hospital

Disclosures:

No relevant conflicts of interest to declare.

Fundamental Research Relating to New Therapeutic Opportunities to Target AML and CML.

9:30 AM

Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable EVI1-CtBP1/2 Interaction and By Repressing Myeloid Regulator CEBPA

Dorien Pastoors, MSc^1,2^*, Marije Havermans^1,2^*, Remco Hoogenboezem, MSc³^*, Roger Mulet-Lazaro, MSc^1,2^*, Duncan Brian, BSc⁴^*, Leonie Smeenk, PhD^1,2^*, Claudia Erpelinck-Verschueren^1,2^*, Stanley van Herk, BSc^1,2^*, Bas Wouters, MD/PhD^1,2^*, Jeroen A.A. Demmers, PhD⁵^*, Johannes Zuber, MD⁶^*, Tariq Enver, PhD⁷^*, Richard WJ Groen^8,9^*, Eric Bindels, PhD¹^* and Ruud Delwel, MD^1,2

¹Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²Oncode Institute, Rotterdam, Netherlands
³Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
⁴Stem Cell Group, UCL Cancer Institute, University College London, London, United Kingdom
⁵Proteomics Center, Erasmus MC, Rotterdam, Netherlands
⁶Research Institute of Molecular Pathology (IMP), Vienna, Austria
⁷University College London Cancer Institute, London, United Kingdom
⁸Hematology, Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands
⁹Cancer Center Amsterdam, Amsterdam, Netherlands

9:45 AM

EVI1 Promotes Immune-Evasive Microenvironment Via Cyclin D1 in Acute Myeloid Leukemia

Yosuke Masamoto, MD, PhD¹, Akira Chiba, MD, PhD¹, Toshiya Hino, MD, PhD²^*, Hiroki Hayashida, MD²^*, Hideaki Mizuno, MD¹^*, Tomohiko Sato, MD, PhD^1,3 and Mineo Kurokawa⁴^*

¹Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
²The University of Tokyo Hospital, Tokyo, TKY, JPN
³Division of Transfusion Medicine and Cell Therapy, The Jikei University Hospital, Tokyo, Japan
⁴Graduate School of Medicine, The University of Tokyo, Bunkyo-Ku, Tokyo, JPN

10:00 AM

Programmed Death-1 Homolog (PD-1H/VISTA) Blockade Confers a Synergistic Anti-Leukemia Effect with PD-1 Blockade

TaeKon Kim, MD¹, Xue Han, PhD²^*, Qianni Hu, PhD³^*, Carly Hedgepath⁴^*, Junshik Hong, MD^4,5, Jihyun Park^3,6^*, Emily F Mason, MD, PhD⁷^* and Lieping Chen, MD, Ph.D.⁸^*

¹Division of hematology/oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
²Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Pelotonia Institute for Immuno-Oncology, OSUCCC – James, The Ohio State University, Columbus, OH
³Vanderbilt University Medical Center, Nashville, TN
⁴Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
⁵Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
⁶Center for Medical Innovation, Seoul National University Hospital, Seoul, Korea, Republic of (South)
⁷Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville
⁸Department of Immunobiology, Yale School of Medicine, New Haven, CT

10:15 AM

CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia

Yinghui Zhu, PhD^1,2^*, Miso Park, PhD³^*, Mariam Murtadha, PhD^1,2^*, Enrico Caserta, PhD^1,2^*, Le Xuan Truong Nguyen, PhD⁴^*, Mahmoud Singer, PhD^1,2^*, Marc Denisse Estepa^1,2^*, Lokesh Nigam, PhD^1,2^*, Ada Alice Dona', PhD^1,2^*, James F Sanchez, PhD¹^*, Theophilus Tandoh, PhD^1,2^*, Man Li, PhD²^*, Bin Zhang, PhD²^*, Ya-Huei Kuo, PhD², Guido Marcucci, MD², John C Williams, PhD³^* and Flavia Pichiorri, PhD^1,2

¹Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
²Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope, Duarte, CA
³Department of Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, CA
⁴Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope, Duarte, CA

10:30 AM

The XPO7/Npat Axis Is a Potential Therapeutic Target for TP53-Mutated AML

Yuichiro Semba, MD, PhD¹^*, Takuji Yamauchi, MD, PhD¹^*, Fumihiko Nakao, MD¹^*, Jumpei Nogami, PhD¹^*, Seishi Ogawa, MD, PhD², Koichi Akashi, MD, PhD¹ and Takahiro Maeda, MD, PhD³

¹Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
²Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto City, Japan
³Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

10:45 AM

TIF1β Enhances Self-Renewal Capacity of BCR-ABL Leukemic Stem Cells and Inhibits the Myeloid Differentiation

Mariko Morii, PhD¹^*, Sho Kubota, PhD¹^*, Mihoko Iimori¹^*, Ai Hamashima¹^*, Kimi Araki, PhD^2,3^* and Goro Sashida, MD, PhD¹

¹Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan
²Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan
³Center for Metabolic Regulation of Healthy Aging, Kumamoto University, Kumamoto, Japan

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

602.O4.6 602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies